Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
AbCellera Biologics ( (ABCL) ) has shared an announcement.
On December 18, 2025, AbCellera Biologics announced a global settlement and patent license agreement with Bruker Corporation that resolves all patent litigation between the two companies. Under the agreement, Bruker will pay AbCellera $36 million upfront and provide ongoing royalty payments on worldwide sales of Bruker’s Beacon Optofluidic platform products for the life of the licensed patents, strengthening AbCellera’s cash position and securing a continuing revenue stream tied to Bruker’s commercial success.
The most recent analyst rating on (ABCL) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.
Spark’s Take on ABCL Stock
According to Spark, TipRanks’ AI Analyst, ABCL is a Neutral.
AbCellera Biologics’ overall stock score reflects significant financial challenges and unattractive valuation due to ongoing losses. While the company has strong liquidity and is transitioning to a clinical-stage biotech, which offers long-term potential, near-term financial pressures and bearish technical indicators weigh heavily on the score.
To see Spark’s full report on ABCL stock, click here.
More about AbCellera Biologics
AbCellera Biologics Inc., based in Vancouver and listed on Nasdaq as ABCL, is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines, with core therapeutic efforts in endocrinology, women’s health, immunology, and oncology.
Average Trading Volume: 5,023,184
Technical Sentiment Signal: Sell
Current Market Cap: $1.04B
Learn more about ABCL stock on TipRanks’ Stock Analysis page.